MX2022006711A - Nuevos inhibidores de braf como rompedores de la paradoja. - Google Patents

Nuevos inhibidores de braf como rompedores de la paradoja.

Info

Publication number
MX2022006711A
MX2022006711A MX2022006711A MX2022006711A MX2022006711A MX 2022006711 A MX2022006711 A MX 2022006711A MX 2022006711 A MX2022006711 A MX 2022006711A MX 2022006711 A MX2022006711 A MX 2022006711A MX 2022006711 A MX2022006711 A MX 2022006711A
Authority
MX
Mexico
Prior art keywords
braf inhibitors
new
paradox
breakers
paradox breakers
Prior art date
Application number
MX2022006711A
Other languages
English (en)
Inventor
Daniel Hunziker
Juergen Wichmann
Cosimo Dolente
David Stephen Hewings
Daniela Krummenacher
Piergiorgio Francesco Tommaso Pettazzoni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022006711A publication Critical patent/MX2022006711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)
  • Luminescent Compositions (AREA)

Abstract

La invención proporciona un compuesto novedoso que tiene la Fórmula general (I) (ver Fórmula) (I) en donde R1-R3 y X son como se definen en la descripción y en las reivindicaciones. El compuesto de Fórmula (I) se puede usar como un medicamento.
MX2022006711A 2019-12-10 2020-12-08 Nuevos inhibidores de braf como rompedores de la paradoja. MX2022006711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214867 2019-12-10
PCT/EP2020/084969 WO2021116050A1 (en) 2019-12-10 2020-12-08 New braf inhibitors as paradox breakers

Publications (1)

Publication Number Publication Date
MX2022006711A true MX2022006711A (es) 2022-07-12

Family

ID=68848068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006711A MX2022006711A (es) 2019-12-10 2020-12-08 Nuevos inhibidores de braf como rompedores de la paradoja.

Country Status (18)

Country Link
US (1) US20220298145A1 (es)
EP (1) EP4073044A1 (es)
JP (1) JP2023505300A (es)
KR (1) KR20220112777A (es)
CN (1) CN114746405B (es)
AR (1) AR120697A1 (es)
AU (1) AU2020403082A1 (es)
BR (1) BR112022010633A2 (es)
CA (1) CA3158541A1 (es)
CL (1) CL2022001492A1 (es)
CO (1) CO2022007621A2 (es)
CR (1) CR20220252A (es)
IL (1) IL292349A (es)
MX (1) MX2022006711A (es)
PE (1) PE20221027A1 (es)
TW (1) TW202136218A (es)
WO (1) WO2021116050A1 (es)
ZA (1) ZA202204092B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220251A (es) * 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos derivados de metilquinazolinona
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024126634A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Process for the preparation of a quinazolinone derivative
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972138A1 (en) * 2008-03-17 2009-09-24 Ambit Biosciences Corporation Raf kinase modulator compounds and methods of use thereof
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CN104640865B (zh) * 2012-09-19 2018-05-11 诺华股份有限公司 作为激酶抑制剂的二氢吡咯烷子基-嘧啶
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
PE20231651A1 (es) * 2020-06-09 2023-10-17 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf

Also Published As

Publication number Publication date
PE20221027A1 (es) 2022-06-16
KR20220112777A (ko) 2022-08-11
CN114746405B (zh) 2024-03-26
AU2020403082A1 (en) 2022-05-12
EP4073044A1 (en) 2022-10-19
CL2022001492A1 (es) 2023-02-24
TW202136218A (zh) 2021-10-01
CA3158541A1 (en) 2021-06-17
BR112022010633A2 (pt) 2022-08-16
US20220298145A1 (en) 2022-09-22
IL292349A (en) 2022-06-01
CO2022007621A2 (es) 2022-08-30
AR120697A1 (es) 2022-03-09
CR20220252A (es) 2022-07-11
JP2023505300A (ja) 2023-02-08
CN114746405A (zh) 2022-07-12
WO2021116050A1 (en) 2021-06-17
ZA202204092B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
MX2022006711A (es) Nuevos inhibidores de braf como rompedores de la paradoja.
CR20220351A (es) Inhibidores de proteínas kras mutantes
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CR20200347A (es) Inhibidores pd-1/pd-l1
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
GEP20237506B (en) Pcsk9 antagonist compounds
CR20210247A (es) Nuevos compuestos heterocíclicos
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
CR20210056A (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
CR20200416A (es) Nuevos compuestos heterocíclicos
AU2009303758A8 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
GEP20227443B (en) Magl inhibitors
GEP20207169B (en) 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
MX2009005881A (es) Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
TR201902435T4 (tr) DGAT1 inhibitör içeren farmasötik bileşimler.
MX2022001004A (es) Inhibidores de enzimas.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
MX2021003427A (es) Nuevos oxadiazoles.